Tag: Albert Bourla

LIVE 12:15 PM ET: Reuters Interviews Pfizer CEO Albert Bourla

Reuters Editor-in-Chief Alessandra Galloni interviews Pfizer CEO Albert Bourla, a 30-year Pfizer veteran and CEO since 2019, at 12:15 p.m. ET on May 11. Pfizer, one of the world’s largest pharmaceutical companies, is the world’s largest supplier of COVID-19 vaccines and the most successful anti-viral therapeutic on the market. Disclosure: Thomson Reuters Foundation Chairman James Smith…


LIVE NOW: Reuters Interviews Pfizer CEO Albert Bourla

Reuters Editor-in-Chief Alessandra Galloni interviews Pfizer CEO Albert Bourla, a 30-year Pfizer veteran and CEO since 2019, at 12:15 p.m. ET on May 11. Pfizer, one of the world’s largest pharmaceutical companies, is the world’s largest supplier of COVID-19 vaccines and the most successful anti-viral therapeutic on the market. Disclosure: Thomson Reuters Foundation Chairman James Smith…


Reuters Interviews Pfizer CEO Albert Bourla

Reuters Editor-in-Chief Alessandra Galloni interviews Pfizer CEO Albert Bourla, a 30-year Pfizer veteran and CEO since 2019, at 12:15 p.m. ET on May 11. Pfizer, one of the world’s largest pharmaceutical companies, is the world’s largest supplier of COVID-19 vaccines and the most successful anti-viral therapeutic on the market. Disclosure: Thomson Reuters Foundation Chairman James Smith…


Hundreds of Drugmakers Call for Reversal of Texas Court Ruling on Abortion Pill

More than 300 current and former biotech and pharmaceutical executives have signed an open letter criticizing a federal Texas judge over his recent decision to suspend FDA approval of the abortion pill mifepristone. “We cannot stay quiet. We call for the reversal of this decision to disregard science, and the appropriate restitution of the mandate…


Pfizer CEO Albert Bourla Tests Positive for COVID-19

Pfizer’s CEO has tested positive for COVID-19, he announced on Aug. 15. “I would like to let you know that I have tested positive for #COVID19,” CEO Albert Bourla wrote on Twitter. Bourla 60, says he has received four doses of his company’s COVID-19 vaccine, which has proven increasingly ineffective against infection from the virus…


EU’s von Der Leyen Can’t Find Texts With Pfizer Chief on Vaccine Deal: Letter

BRUSSELS—European Commission president Ursula von der Leyen is no longer in possession of text messages that she exchanged with Pfizer chief Albert Bourla to seal a COVID-19 vaccine deal, the Commission said in a letter published on Wednesday. In an interview in April 2021, von der Leyen revealed she had exchanged texts with Bourla for…


Pfizer to Ask US Regulators to Authorize Second Booster Due to Waning Effectiveness: CEO

Pfizer plans to ask U.S. regulators to grant emergency use authorization for a second booster of its COVID-19 vaccine, CEO Albert Bourla said March 11. “Clearly there is a need in an environment of Omicron to boost the immune response,” Bourla said on CNBC’s “Squawk Box.” Pfizer’s vaccine waned over time in protection against both…


Pfizer CEO Says an Omicron-Targeted Vaccine Will Be Ready in March

Albert Bourla, the CEO of Pfizer, said a COVID-19 vaccine that specifically targets the Omicron variant of the virus as well as already circulating variants “will be ready in March.” “This vaccine will be ready in March. I don’t know how if we will need it, I don’t know how it will be used, but…


Pfizer CEO: ‘I Think We Will Need the Fourth Dose’ of COVID-19 Vaccine

Pfizer CEO Albert Bourla said during a Wednesday interview that he believes a fourth dose of the COVID-19 vaccine will likely need to be required amid concerns over the Omicron variant. “I think we will need the fourth dose. I’ve said that multiple times. With the previous, I was projecting that that will be on…


Pfizer Seeks FDA Authorization for COVID-19 Booster Shots in 16-, 17-Year-Olds

Pfizer CEO and Chairman Albert Bourla on Tuesday announced that the company and its partner BioNTech have submitted a request to the U.S. Food and Drug Administration (FDA) seeking to expand authorization for its COVID-19 booster shot for use in 16- and 17-year-olds. It comes after U.S. regulators last week expanded the eligibility for a…